Since adding the Google Fitbit Air to my arsenal, I've been wearing it almost all the time. The only times I forgot to strap it on were a night or two when I left it on the charging puck because I was ...

I tested the best audio streaming services, from Apple Music to Spotify, to see which most deserves your monthly subscription ...

Many budget allocation strategies assume that every channel follows the same pattern: the first dollar is the most productive, and each additional dollar yields a slightly lower return. The charts ...

Instagram is expanding its Your Algorithm feature to the main feed, enabling users to view and modify the topics that drive their content recommendations The update utilizes large language models to ...

The equity risk premium has effectively vanished. While it is a signal worth heeding, it is not cause for immediate alarm, particularly for portfolios that are genuinely diversified. In recent weeks ...

Wall Street is chasing AI momentum and leaving much of the market in the dust, but the smaller stocks are keeping up. The Invesco S&P 500 Equal Weight ETF, which counts every S&P 500 stock as if they ...

Say goodbye to the Google search bar you’ve known for 25 years. The company is making it bigger and more interactive. The redesign is a response to AI, which has changed the way people search. Instead ...

For 25 years, Google Search has trained people to type a few keywords into a blank white box and click through a list of blue links. Now, the company wants that box to behave more like an AI assistant ...

What’s unusual today is the degree of divergence between individual stocks and the cap-weighted index. The single most damaging decision most investors make during periods of falling stock market ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ...